Lilly Shorts Capitulate as MRK Steals the Week's Spotlight

Options tell a similarly uncrowded story. The put/call ratio has eased to 1.26, essentially flat against its 20-day average of 1.26 — a z-score of nearly zero. That's a notable de-escalation from the 1.34–1.37 range printed in late July and early August, when defensive hedging was more visible. The 52-week PCR range runs from 0.76 to 1.37, so the current reading sits in the upper half but well away from extremes. Options traders are not pressing new bets in either direction.

The Street remains firmly in the bull camp, though the most recent analyst moves have been incremental rather than revelatory. Following the August 5 earnings beat — where the stock jumped 6.8% on the day and extended 9.4% over the following week — Truist raised its target to $1,376 and Wells Fargo lifted to $1,330, both maintaining positive ratings. Cantor Fitzgerald went further, moving to $1,410. Those three actions, all within three weeks of today, collectively push the consensus mean target to $1,315. With the stock at $1,234, that implies roughly 6.5% to the average target — a modest gap for a name this consensus-loved, but it leaves 18 buys in the count with no sells. The factor score on analyst recommendation differential ranks in the 98th percentile versus the broader universe. Valuation remains stretched: the trailing P/E runs at 27x and EV/EBITDA at 22x, though both have compressed slightly over the past 30 days as earnings have grown into the multiple. The ORTEX short score has dropped sharply to 29.3 from 31.4 a week ago, consistent with the covering trend and signalling reduced bearish pressure across all composite inputs.

Insider activity over the past 90 days has been uniformly in one direction: selling. The divisional president sold $7.6 million of stock on August 17 at $1,175. The chief accounting officer sold $2.4 million on August 10. The general counsel sold $6 million on August 7, the day after the earnings-driven spike. Net insider sales over 90 days total approximately $19.3 million. None of these transactions are unusual in size for a $1,200 stock, and significance scores are low across the board — these read as scheduled or opportunistic monetisation following the stock's recovery from the August trough, not a directional call. The Lilly Endowment, the 10.1% anchor holder, trimmed 1.52 million shares as of June 30 but remains the largest single owner by a wide margin.

Against the peer backdrop, MRK's 15.7% weekly surge — likely driven by stock-specific catalysts — makes LLY's flat-to-slightly-positive week look like consolidation rather than weakness. JNJ and NOVN both gained roughly 0.7–2.2% on the week, so LLY's 0.6% advance keeps it broadly in step with the large-cap pharma complex outside of Merck's outlier move. The Q3 earnings date is October 29, giving the stock nine weeks of runway before the next fundamental test. Between now and then, the Foundayo UK commercial ramp and NHS pricing negotiations — flagged in the prior report as a live catalyst — will be the incremental datapoints worth tracking most closely.